Compare Eli Lilly And Co (LLY) vs Global X Defense Tech ETF (SHLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Global X Defense Tech ETF — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while Global X Defense Tech ETF trades at $59.87 (market cap $6.29B). The key difference: Eli Lilly And Co is far larger — about 165.3× Global X Defense Tech ETF's market cap, and Eli Lilly And Co pays a 0.59% dividend while Global X Defense Tech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Global X Defense Tech ETF for 44 Days on average.
| LLY | SHLD | |
|---|---|---|
Market Cap | $1.04T | $6.29B |
Volume | 3,064,878 | 1,133,252 |
Sector | Health | Sector/Thematic |
52-Week High | $1.28K | $78.02 |
52-Week Low | $799.57 | $58.20 |
Typical Hold Time | 93 Days | 44 Days |
Enterprise Value | $1.09T | — |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company demonstrates exceptional profitability with 83.4% gross margins and 33.53% net income margins, supported by dominant positioning in weight-loss and diabetes treatments. Recent clinical trial successes for next-generation drugs and expanded FDA approvals reinforce growth prospects.
LLY presents compelling growth potential with analyst consensus target of $1,350 representing 15% upside, though elevated valuations (P/E 39.26) and increasing competition in obesity drugs pose risks. Strong institutional support (73% buy ratings) and positive pipeline developments support continued momentum, but investors should monitor execution risks and market saturation concerns.
SHLD (Global X Defense Tech ETF) trades at $59.87, up 1.92% today, but technical indicators show a bearish trend with moving averages signaling strong selling pressure. The ETF focuses on defense technology with exposure to global defense firms, benefiting from increased defense spending trends. Recent institutional buying activity indicates growing investor interest in the defense sector.
The outlook for SHLD appears mixed - strong geopolitical tailwinds support defense spending growth, but technical weakness suggests near-term pressure. Key opportunities include exposure to rising global defense budgets, while risks involve sector volatility and geopolitical uncertainties affecting defense stocks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Global X Defense Tech ETF
SHLD tracks the Global X Defense Tech Index, targeting companies that lead the technological transformation of the defense sector. It focuses on pure-play innovators in cybersecurity, artificial intelligence, robotics, and advanced military systems, excluding traditional commercial aerospace to maintain a high level of thematic purity.
Read more on SHLD →
